A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01468636 |
Recruitment Status
:
Terminated
(There was no clear benefit but numerous side effects.)
First Posted
: November 9, 2011
Last Update Posted
: November 2, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Genital Warts HPV | Drug: Oral Zinc Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Care Provider) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Controlled Trial to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts |
Study Start Date : | November 2011 |
Actual Primary Completion Date : | January 2012 |
Actual Study Completion Date : | January 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Oral Zinc |
Drug: Oral Zinc
200 mg BID of oral zinc gluconate x 8 weeks
|
Placebo Comparator: Placebo |
Drug: Placebo
200mg BID x 8 weeks
|
- complete clearance of genital warts [ Time Frame: 8 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults age 19 and over
- Clinical diagnosis of genital warts requiring treatment based on clinician evaluation
- Fluency in English
- Available within four days of the intended 8 week follow-up visit
Exclusion Criteria:
- Individuals under the age of 19
- Pregnant women
- Known contraindication to zinc Signs of copper/iron deficiency which include anemia and neutropenia which are characterized by tiredness, fatigue and light headedness.
- Diseases that alter zinc metabolism or absorption eg. type II diabetes mellitus, Crohn's disease, chronic leg ulcers
- Clients who are currently taking zinc for therapeutic purposes or have taken zinc in the last two months for therapeutic purposes
- Clients who have received standard of care treatment for their warts in the past month

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01468636
Canada, British Columbia | |
BC Centre for Disease Control | |
Vancouver, British Columbia, Canada, V5Z 4R4 |
Principal Investigator: | Richard Lester | University of British Columbia |
Responsible Party: | University of British Columbia |
ClinicalTrials.gov Identifier: | NCT01468636 History of Changes |
Other Study ID Numbers: |
H11-01758 H11-01758 ( Other Identifier: UBC IRB number ) |
First Posted: | November 9, 2011 Key Record Dates |
Last Update Posted: | November 2, 2016 |
Last Verified: | October 2016 |
Keywords provided by University of British Columbia:
Warts HPV Zinc |
Additional relevant MeSH terms:
Warts Condylomata Acuminata Papillomavirus Infections DNA Virus Infections Virus Diseases Skin Diseases, Viral Tumor Virus Infections Skin Diseases, Infectious |
Skin Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Zinc Trace Elements Micronutrients Growth Substances Physiological Effects of Drugs |